

## Перелік літературних джерел

1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med* 2020.
2. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020.
3. Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. *MMWR Recomm Rep* 2020; 69:1.
4. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *JAMA* 2020.
5. Brown PD, Gondi V, Pugh S, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. *J Clin Oncol* 2020; 38:1019.
6. Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *Lancet* 2020; 394:2271.
7. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. *Lancet* 2019; 394:1713.
8. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet* 2019; 394:1940.
9. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med* 2019; 381:1809.
10. Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *J Clin Oncol* 2020; 38:1126.
11. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2019; 381:1995.
12. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. *Obstet Gynecol* 2020; 135:e51.
13. Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. *MMWR Morb Mortal Wkly Rep* 2019; 68:439.
14. Zeitlin J, Egorova NN, Janevic T, et al. The Impact of Severe Maternal Morbidity on Very Preterm Infant Outcomes. *J Pediatr* 2019; 215:56.
15. Shi H, Enriquez A, Rapadas M, et al. NAD Deficiency, Congenital Malformations, and Niacin Supplementation. *N Engl J Med* 2017; 377:544.
16. Wang ME, Biondi EA, McCulloh RJ, et al. Testing for Meningitis in Febrile Well-Appearing Young Infants With a Positive Urinalysis. *Pediatrics* 2019; 144.
17. Nugent J, Childers M, Singh-Miller N, et al. Risk of Meningitis in Infants Aged 29 to 90 Days with Urinary Tract Infection: A Systematic Review and Meta-Analysis. *J Pediatr* 2019; 212:102.
18. [www.cochrane.org](http://www.cochrane.org)
19. [www.medscape.com](http://www.medscape.com)
20. [www.nejm.org](http://www.nejm.org)
21. [www.obgyn.net](http://www.obgyn.net)

22. <http://aappolicy.aappublications.org/>
23. <http://www.neonatology.org/>
24. <http://www.uihealthcare.com/depts/med/pediatrics/iowaneonatologyhandbook/index.ht>
25. <http://www.sign.ac.uk/guidelines/fulltext/50/index.html>
26. <http://www.pedialink.org/pedialink/neopix/index2.cfm>.
27. **German Physicians Board** “Beurteilungskriterien für Leitlinien in der Medizinischen Versorgung <http://www.uni-duesseldorf.de/AWMF/awmf-fr2.htm>; <http://leitlinien.net/>
28. **Calgary Regional Health Authority** “Guideline Development Template” <http://www.crha-health.ab.ca/clin/cme/cpg/cpgdevproc.pdf>
29. **New Zealand Guidelines Group**  
[www.nzgg.org.nz/index.cfm?fuseaction=fuseaction\\_10&fusesubaction=docs&documentid=22](http://www.nzgg.org.nz/index.cfm?fuseaction=fuseaction_10&fusesubaction=docs&documentid=22)
30. **University of Melbourne Guideline Development Group**  
[http://www.rch.org.au/clinicalguide/index.cfm?doc\\_id=5033](http://www.rch.org.au/clinicalguide/index.cfm?doc_id=5033)
31. **US National Guideline Clearinghouse™ (NGC)**  
[http://www.guideline.gov/browse/guideline\\_index.aspx](http://www.guideline.gov/browse/guideline_index.aspx)
32. **Royal College of Obstetricians and Gynaecologists**  
<http://www.rcog.org.uk/index.asp?PageID=8>
33. **Neonatology guidelines, Geneva Foundation for Medical Education and Research**  
[http://www.gfmer.ch/Guidelines/Neonatology/Neonatology\\_mt.htm](http://www.gfmer.ch/Guidelines/Neonatology/Neonatology_mt.htm)